Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Once more into the breach

Flamel Technologies S.A. hinted last week that Bristol-Myers Squibb Co.'s decision to return rights to Basulin extended-release insulin was due to a shift in the pharma company's business strategy away from the primary care market. But earlier in the week at the Bear Stearns healthcare conference,

Read the full 461 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers